GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Venus Medtech (Hangzhou) Inc (HKSE:02500) » Definitions » Price-to-Free-Cash-Flow

Venus Medtech (Hangzhou) (HKSE:02500) Price-to-Free-Cash-Flow : N/A (As of Jun. 19, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Venus Medtech (Hangzhou) Price-to-Free-Cash-Flow?

As of today (2024-06-19), Venus Medtech (Hangzhou)'s share price is HK$5.62. Venus Medtech (Hangzhou)'s Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-2.18. Hence, Venus Medtech (Hangzhou)'s Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Venus Medtech (Hangzhou)'s Price-to-Free-Cash-Flow or its related term are showing as below:

HKSE:02500's Price-to-Free-Cash-Flow is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 32.535
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Venus Medtech (Hangzhou)'s Free Cash Flow per Share for the six months ended in Dec. 2023 was HK$-1.22. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was HK$-2.18.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -27.70% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was -32.10% per year.

During the past 7 years, Venus Medtech (Hangzhou)'s highest 3-Year average Free Cash Flow per Share Growth Rate was -25.50% per year. The lowest was -50.50% per year. And the median was -38.00% per year.


Venus Medtech (Hangzhou) Price-to-Free-Cash-Flow Historical Data

The historical data trend for Venus Medtech (Hangzhou)'s Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Venus Medtech (Hangzhou) Price-to-Free-Cash-Flow Chart

Venus Medtech (Hangzhou) Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial - - - - -

Venus Medtech (Hangzhou) Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Venus Medtech (Hangzhou)'s Price-to-Free-Cash-Flow

For the Medical Devices subindustry, Venus Medtech (Hangzhou)'s Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Venus Medtech (Hangzhou)'s Price-to-Free-Cash-Flow Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Venus Medtech (Hangzhou)'s Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Venus Medtech (Hangzhou)'s Price-to-Free-Cash-Flow falls into.



Venus Medtech (Hangzhou) Price-to-Free-Cash-Flow Calculation

Venus Medtech (Hangzhou)'s Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=5.62/-2.18
=N/A

Venus Medtech (Hangzhou)'s Share Price of today is HK$5.62.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Venus Medtech (Hangzhou)'s Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-2.18.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Venus Medtech (Hangzhou)  (HKSE:02500) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Venus Medtech (Hangzhou) Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Venus Medtech (Hangzhou)'s Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Venus Medtech (Hangzhou) (HKSE:02500) Business Description

Traded in Other Exchanges
Address
No. 88, Jiangling Road, Room 311, 3rd Floor, Block 2, Binjiang District, Hangzhou, CHN, 310051
Venus Medtech (Hangzhou) Inc is engaged in the development and commercialization of transcatheter solutions for structural heart diseases. It has two TAVR products on the market, namely VenusA-Valve, and VenusA-Plus. VenusA-Valve is its first-generation TAVR device, which is used to treat severe Aortic Stenosis (AS) using a transcatheter approach. VenusA-Plus is an upgraded product of VenusA-Valve. Geographically all of the revenue is derived from Mainland China.
Executives
Zeng Min Frank 2201 Interest of corporation controlled by you
Zi Zhenjun 2201 Interest of corporation controlled by you
Ming Zhi Investments (bvi) Limited 2101 Beneficial owner
Ming Zhi Investments Limited 2201 Interest of corporation controlled by you
Qiming Venture Partners Iii, L.p. 2201 Interest of corporation controlled by you
Qiming Corporate Gp Iii, Ltd. 2201 Interest of corporation controlled by you
Qiming Gp Iii, L.p. 2201 Interest of corporation controlled by you
Dcp Capital Partners, L.p. 2201 Interest of corporation controlled by you
Dcp General Partner, Ltd 2201 Interest of corporation controlled by you
Dcp, Ltd. 2201 Interest of corporation controlled by you
Liu Haifeng David 2201 Interest of corporation controlled by you
Muheng Capital Partners (hong Kong) Limited 2101 Beneficial owner
Red Giant Limited 2201 Interest of corporation controlled by you
Wolhardt Julian Juul 2201 Interest of corporation controlled by you
Horizon Binjiang Llc 2101 Beneficial owner

Venus Medtech (Hangzhou) (HKSE:02500) Headlines

No Headlines